Anzeige
Mehr »
Login
Samstag, 15.05.2021 Börsentäglich über 12.000 News von 658 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 855648 ISIN: JP3347200002 Ticker-Symbol: SH0 
Frankfurt
14.05.21
18:43 Uhr
43,200 Euro
+0,600
+1,41 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
SHIONOGI & CO LTD Chart 1 Jahr
5-Tage-Chart
SHIONOGI & CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
42,80044,40012:38

Aktuelle News zur SHIONOGI Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiShionogi & Co. reports FY results2
MoURGENT: Japan's Shionogi says looking to provide COVID-19 vaccine this year1
MoJapan's Shionogi may roll out COVID vaccines this year: Kyodo1
SHIONOGI Aktie jetzt für 0€ handeln
MoJapan's Shionogi may roll out COVID vaccines this year -Kyodo1
01.02.Shionogi & Co., Ltd. 2021 Q3 - Results - Earnings Call Presentation11
01.02.Shionogi & Co. reports 9M results6
26.01.UPDATE 1-Japan's Shionogi sells coronavirus drug rights to U.S. biotech BioAge8
26.01.Japan's Shionogi sells coronavirus drug rights to U.S. biotech BioAge2
23.12.20Shionogi's novel antibiotic added to UK's pilot subscription reimbursement model3
22.12.20UK selects Shionogi's Fetcroja for antimicrobial reimbursement scheme-
21.12.20Shionogi's Novel Antibiotic, Fetcroja (cefiderocol), Has Been Selected by UK's NICE / NHSE&I as Part of an Antimicrobial Subscription Style Reimbursement Model518For UK Medical and Pharma Trade Media Only The National Institute for Health and Care Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) have recognised the...
► Artikel lesen
16.12.20Shionogi Begins Coronavirus Vaccine Clinical Trial6
13.10.20Shionogi USA: Shionogi Announces Publication of Two Studies in The Lancet Infectious Diseases Highlighting the Efficacy and Safety of FETROJA for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options384Shionogi announces publication of data from two of its clinical trials; APEKS-NP and CREDIBLE-CR in the journal The Lancet Infectious Diseases APEKS-NP demonstrated that FETROJA (cefiderocol)...
► Artikel lesen
01.10.20Shionogi Announces Publication of a New Systematic Review in CHEST Highlighting the Importance of Early, Appropriate Therapy to Improve Meaningful Outcomes Like Mortality in Patients With Severe Bacterial Infections368The results underscore the importance of providing appropriate therapy early in the course of infection to improve meaningful outcomes such as mortality and provide support for the recommended...
► Artikel lesen
15.09.20Shionogi & Co., Ltd.: Shionogi Launches FETCROJA (cefiderocol) in the United Kingdom for the Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options458Shionogi announces the launch of FETCROJA (cefiderocol) in the United Kingdom (UK) for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options1...
► Artikel lesen
27.07.20Ping An Signs Agreement with Shionogi to Launch Joint Ventures470HONG KONG and SHANGHAI, July 27, 2020 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEx:2318; SSE:601318) is pleased to announce that...
► Artikel lesen
06.07.20AIM ImmunoTech Inc.: AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19814OCALA, FL / ACCESSWIRE / July 6, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that is has signed a material transfer and research agreement with Japan's National Institute of Infectious...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1